Last reviewed · How we verify
narmafotinib dose comparison
At a glance
| Generic name | narmafotinib dose comparison |
|---|---|
| Sponsor | Amplia Therapeutics Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- narmafotinib dose comparison CI brief — competitive landscape report
- narmafotinib dose comparison updates RSS · CI watch RSS
- Amplia Therapeutics Limited portfolio CI